Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation

Nurix Therapeutics, Inc. (NASDAQ: NRIX ) leads in targeted protein modulation with its proprietary DELigase platform. This way, it develops therapies for cancer and inflammatory conditions. NRIX offers solutions for challenging conditions resistant to conventional treatments, using the natural processesMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio U ...